SCHEMBL898980

SCHEMBL898980

CC(C)c1cc(C2CC3CC2CC3c2ccccc2)ccc1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
HSP90AA1 P07900 3/20 0.38
HSP90AB1 P08238 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
HTR2C P28335 1/20 0.35
KDM1A O60341 3/20 0.35
PLG P00747 1/20 0.34
PLAU P00749 1/20 0.34
PLAT P00750 1/20 0.34
KLK1 P06870 1/20 0.34
MAOA P21397 2/20 0.33
MAOB P27338 2/20 0.33
CYP2C19 P33261 2/20 0.33
HDAC4 P56524 1/20 0.33
CYP2B6 P20813 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL899694 0.92 MEN1 (0.42) GABRA1GABRB2HSP90AA1HSP90AB1MEN1
SCHEMBL899747 0.85 LTB4R (0.34) GABRA1GABRB2HSP90AA1HSP90AB1MEN1
SCHEMBL900013 0.81 GAA (0.35) GABRA1GABRB2HSP90AA1HSP90AB1MEN1
SCHEMBL8509094 0.80 MEN1 (0.44) MEN1KMT2APOLBGAAHTR2C
SCHEMBL899643 0.78 MEN1 (0.38) GABRA1GABRB2HSP90AA1HSP90AB1MEN1
SCHEMBL899786 0.78 MAPT (0.42) GABRA1GABRB2HSP90AA1HSP90AB1MEN1
SCHEMBL900068 0.77 MEN1 (0.68) GABRA1GABRB2HSP90AA1HSP90AB1MEN1
SCHEMBL8512440 0.77 MEN1 (0.38) GABRA1GABRB2HSP90AA1HSP90AB1MEN1
SCHEMBL899901 0.76 TRPV1 (0.34) HSP90AA1HSP90AB1MEN1KMT2APOLB
SCHEMBL899180 0.76 TRPV1 (0.34) HSP90AA1HSP90AB1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9261781-B2 Preparation of norbornane-based PAC ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2016-02-16 US claimed
US-20130323640-A1 Preparation of Norbornane-based PAC Ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2013-12-05 US claimed
US-9261781-B2 Preparation of norbornane-based PAC ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2016-02-16 US disclosed
US-20130323640-A1 Preparation of Norbornane-based PAC Ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2013-12-05 US disclosed
US-8530133-B2 Preparation of norbornane-based PAC ballasts PROMERUS, LLC (US) 2013-09-10 US disclosed
EP-2622410-A1 NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC Promerus, LLC (US) 2013-08-07 EP disclosed
US-20120135352-A1 Preparation of Norbornane-based PAC Ballasts PROMERUS LLC (US) 2012-05-31 US disclosed
WO-2012044719-A1 NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC PROMERUS LLC (US) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135352-A1 Preparation of Norbornane-based PAC Ballasts NBAS, PHB2, BDNF GABRA1 41/4885GABRB2 7/4885HSP90AA1 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.